DDR1
DDR1 Molekülinformation
| Englischer Name | Discoidin domain receptor 1 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 5 | Target-Alias | Epithelial discoidin domain-containing receptor 1，Epithelial discoidin domain receptor 1，CD167 antigen-like family member A，Cell adhesion kinase，Discoidin receptor tyrosine kinase，HGK2，Mammary carcinoma kinase 10，MCK-10，Protein-tyrosine kinase 3A，Protein-tyrosine kinase RTK-6，TRK E，Tyrosine kinase DDR，Tyrosine-protein kinase CAK，CD167a，CD167 Antigen-Like Family Member A，TRKE，RTK6，PTK3A Protein Tyrosine Kinase 3A，PTK3A，NTRK4，Neurotrophic Tyrosine Kinase， Receptor， Type 4，Neuroepithelial Tyrosine Kinase，NEP，MCK10，EDDR1，Discoidin Domain Receptor Tyrosine Kinase 1，Discoidin Domain Receptor Family， Member 1，CD167a Antigen，CAK，CD167 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Discoidin domain receptor 1 |
| Target-Alias | Epithelial discoidin domain-containing receptor 1，Epithelial discoidin domain receptor 1，CD167 antigen-like family member A，Cell adhesion kinase，Discoidin receptor tyrosine kinase，HGK2，Mammary carcinoma kinase 10，MCK-10，Protein-tyrosine kinase 3A，Protein-tyrosine kinase RTK-6，TRK E，Tyrosine kinase DDR，Tyrosine-protein kinase CAK，CD167a，CD167 Antigen-Like Family Member A，TRKE，RTK6，PTK3A Protein Tyrosine Kinase 3A，PTK3A，NTRK4，Neurotrophic Tyrosine Kinase， Receptor， Type 4，Neuroepithelial Tyrosine Kinase，NEP，MCK10，EDDR1，Discoidin Domain Receptor Tyrosine Kinase 1，Discoidin Domain Receptor Family， Member 1，CD167a Antigen，CAK，CD167 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 5 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
DDR1 Produktliste
- Attribut
Protein (3)
- Produktbibliothek
Online (3)
- Spezies
Human (2)Mouse (1)
- Etikett
Fc Tag (2)His Tag & Avi Tag (1)
- Marker
Unconjugated (2)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Biotinylated Human DDR1 Protein, His,Avitag™ (MALS & BLI verified) |  |  |  |  In den Warenkorb legen | |
| Human | HEK293 | Human DDR1 Protein, Fc Tag (BLI verified) |  | | | In den Warenkorb legen | |
 Mouse | HEK293 | Mouse DDR1 Protein, Fc Tag |  | |  | In den Warenkorb legen |
Gesamtmenge3
- 1
DDR1 Molekülhintergrund
Discoidin domain receptor 1 (DDR1) is a member of DDRs, which are members of the receptor tyrosine kinase (RTK). Upon collagen binding, DDR1 undergoes tyrosine autophosphorylation, which consequently triggers downstream genetic and cellular pathways and plays critical roles in the regulation of cellular morphogenesis, differentiation, proliferation, adhesion, migration, and invasion. Research shows that DDR1 is closely related to various human diseases including cancer, fibrosis, atherosclerosis, and other inflammatory disorders. New generation DDR1 inhibitors targeting the allosteric sites outside of the canonical ATP-binding pocket or extracellular domain (allosteric inhibitors) may offer a new opportunity for selective DDR1 inhibition therapy development.
DDR1 Molekülalias
CD167a
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Ensavatatug | PRTH-101 | Phase 1 Clinical | Parthenon Therapeutics Inc, The George Washington University Milken Institute School Of Public Health (Gwu) | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| ICP-033 | ICP-033 | Phase 1 Clinical | Beijing Innocare Pharma Tech Co Ltd | Solid tumours | Details |
| AVI-4015 | AVI-4015 | Phase 1 Clinical | Avixgen | Dry Eye Syndromes | Details |
| AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation